Skip to content

Amylyx Pharmaceuticals, Inc.

AMLX

CIK 0001658551

← back to feed
Revenue (TTM)
$416K
−100.0% YoY Q1 Apr 2026
Net Income (TTM)
−$153.02M
+52.0% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$1.62
+65.5% YoY Q1 Apr 2026
Gross Margin
100.0%
Q1 Apr 2026
Operating Margin
-38,573.6%
Q1 Apr 2026
Net Margin
-36,783.7%
Q1 Apr 2026
Free Cash Flow (TTM)
−$82.94M
Q1 Apr 2026
Cash
$229.14M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
111.19M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings